Green Chemistry in the Pharmaceutical Industry

Preț: 660,00 lei
Disponibilitate: la comandă
ISBN: 9783527324187
Editura:
Anul publicării: 2010
Pagini: 368

DESCRIERE

Edited by three of the world's leading pharmaceutical scientists, this is the first book on this important and hot topic, containing much previously unpublished information. As such, it covers all aspects of green chemistry in the pharmaceutical industry, from simple molecules to complex proteins, and from drug discovery to the fate of pharmaceuticals in the environment. Furthermore, this ready reference contains several convincing case studies from industry, such as Taxol, Pregabalin and Crestor, illustrating how this multidisciplinary approach has yielded efficient and environmentally-friendly processes. Finally, a section on technology and tools highlights the advantages of green chemistry.

Introduction to Green Chemistry in the Pharmaceutical Industry
Metrics and Green Chemistry Tools
Issues with Solvent and Solvent Selection
Technologies to Drive Green Chemistry Performance
Green Technology Assessment of Biologics Manufacture
Green Manufacturing Process to make JanuviaTM
Green Manufacturing Process to make TaxolTM
Green Manufacturing Process to make PregabalinTM
Green Manufacturing Process to make CrestorTM
Green Synthesis of Radaxafine
Green Synthesis of Brivanib Alaninate
Environmental and Regulatory Aspects
Future trends towards a Greener Pharmaceutical Industry

Peter Dunn is the global head of Green Chemistry at Pfizer. He did his PhD with Professor Charles Rees at Imperial College, London followed by postdoctoral research with Professor Albert Eschenmoser (ETH, Zurich) and Henry Rapoport (University of California, Berkeley). He joined Pfizer in 1989 and worked in the Chemical R&D department for 17years during which time he became the inventor of processes to make a number of drugs including ViagraTM and EnablexTM. He took up his current post in Green Chemistry in 2006 and became co-chair of the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable in 2007.

Michael Williams joined Pfizer in 1972 following his PhD with Professor Charles Rees (University of Liverpool), and rose to become Executive Director and Departmental Head of UK Chemical R&D in 2003. His mid-career responsibilities included the Medicinal Chemistry interface, outsourcing initiatives and technology adoption. In addition to his experience with about 50 early drug candidates, he played a significant role in the late development, filing and commercialization of many agents including ZoloftTM, ViagraTM and RelpaxTM. Since retiring from Pfizer in late 2007, he has become an independent CMC consultant.

Andy Wells is a Principal Scientist in the AstraZeneca Global Process R&D Group. Following a BSc and PhD at Essex University he joined Chemical Development at SmithKline & French in 1986, (SmithKline Beecham in 1989). Experienced in all aspects of organic synthesis and scale-up, he has special interests in chemo-catalysis, biocatalysis and green chemistry. Whilst at SmithKline Beecham he won a corporate Green Chemistry/Technology award in 1999. He currently leads the AstraZeneca Green Chemistry group and is co-chair of American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable. He is also on the international advisory board of the journal, ChemSusChem.

RECENZII

Spune-ne opinia ta despre acest produs! scrie o recenzie
Created in 0.0335 sec